A pre-specified interim analysis showed dual primary endpoint success, with improved PFS and OS versus physician’s-choice chemotherapy in taxane-progressed advanced TNBC. BL-B01D1-307 was a randomized ...

Pathological complete response at surgery was higher with INT230-6 pre-treatment plus Keynote-522 (5/7; 71.4%) than with Keynote-522 alone (2/6; 33%), with one evaluation pending. Grade ≥3 adverse ...

Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ...

March 12, 2026 7:30am EDT Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ("SOC") ...

It may be best not to go off-script when it comes to breast cancer. Roughly 1 in 8 US women are expected to be diagnosed with invasive breast cancer at some point. It’s the most common cancer in women ...

We are curing more cancers than we used to,” Cottrill said. “Recurrent cancers are more challenging to cure than cancers that ...

About 50% of triple-negative breast cancer (TNBC) patients develop resistance to therapy. When resistance arises, tumors are more likely to come back after the original treatment, significantly ...

An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in ...